In gene therapy of the ADA, we transform the lymphocytes with the functional copy of the ADA. This process is done inside the lab in the cell culture set up.
These cells are then injected back in the patient. However, these cells are not immortal and will die after their life span is over.
Thus, the patient will need periodic infusion of the genetically engineered lymphocytes.